We are proud to make it available now without charge for academic research
San Francisco, CA (PRWEB) March 12, 2013
Medrio announces its web based Electronic Data Capture (EDC) Software for Clinical Research is now available without charge to universities. Through its Medrio Scholars program, Medrio's EDC software is now free for investigator initiated studies that are university and/or government funded.
"When researchers use Medrio at University, they are much more likely to select Medrio in industry and they get a professional, fully validated, HIPAA and 21 CFR Part 11 compliant EDC tool for free," said Michael Farr, Medrio's Manager of Medrio Scholars. "Getting a study database is as simple as visiting scholars.medrio.com and entering an email address."
Medrio's EDC software enables the collection and management of data for clinical trials, registries, retrospective studies, and patient web surveys. University researchers can create and manage their clinical study data collection themselves, without programming.
Unlike other EDC offerings available to academic researchers, Medrio supports extensive study and data management tools, is fully validated and meets the requirements for electronic records and signatures (21 CFR Part 11), HIPAA (Health Insurance Portability and Accountability Act) and the European and Swiss Safe harbor frameworks.
"Medrio has been used successfully in Phase I-IV trials, registries, and other clinical studies by 12 of the top 20 global biopharmaceutical companies, and dozens of universities. We are proud to make it available now without charge for academic research," said Mike Novotny, Medrio's CEO.
About Medrio, Inc.
Medrio offers an integrated eClinical Software as a Service (SaaS) platform with a fully hosted Electronic Data Capture (EDC) system that drastically reduces study timelines and costs by putting study managers in control of their studies. By enabling studies to be built completely online without the need for any custom development, Medrio eClinical software allows studies to be ready in days instead of weeks. Medrio has been used successfully in Phase I-IV trials, registries, and other clinical studies by a number of leading contract research organizations (CROs), as well as biopharmaceutical and device companies. Founded in 2005, Medrio is headquartered in the San Francisco Bay Area. For more information visit http://www.medrio.com.